---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-026303"
form_type: "8-K"
ticker: "RYTM"
cik: "0001649904"
company_name: "RHYTHM PHARMACEUTICALS, INC."
filed_at: "2024-02-22T23:59:59+00:00"
generated_at: "2026-06-05T19:33:22.727215+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Rhythm Pharma Q4 IMCIVREE rev $24.2M; reports material weakness in IT controls

## Summary
- Q4 2023 net product revenue $24.2M (FY2023 $77.4M) vs $8.8M Q4 2022; net loss $41.6M ($0.70/share).
- Cash $275.8M at Dec 31, 2023; 2024 non-GAAP op expense guidance $250-270M.
- Material weakness in IT general controls over user access and program change management expected in 10-K.
- Completed enrollment in Phase 3 hypothalamic obesity trial (N=120); top-line data 1H2025.
- Entered global licensing deal for oral MC4R agonist LB54640; IND accepted for RM-718.

## SEC filing metadata
- accession: 0001104659-24-026303
- form_type: 8-K
- ticker: RYTM
- cik: 0001649904
- company_name: RHYTHM PHARMACEUTICALS, INC.
- filed_at: 2024-02-22T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649904/000110465924026303/0001104659-24-026303-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649904/000110465924026303/tm246832d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-026303
- JSON: https://secwatch.observer/filing/0001104659-24-026303.json
- Plain text: https://secwatch.observer/filing/0001104659-24-026303.txt

## Key facts
- Earnings Releases
  RHYTHM PHARMACEUTICALS, INC. reported fourth quarter and full year ended December 31, 2023 results: revenue $24.2 million.
  - Period: fourth quarter and full year ended December 31, 2023
  - Revenue: $24.2 million
  - Result: reported results
  source text: Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update -- Fourth quarter 2023 net revenue from global sales of IMCIVREE ® (setmelanotide) of $24.2 million -- -- Enrollment completed in 120-patient, pivotal cohort of Phase 3 setmelanotide trial in hypothalamic obesity; top-line data on track for 1H2025 -- -- Announced Phase 3
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649904/000110465924026303/0001104659-24-026303-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.